Approximately 96% of patients with GBM have IDH1 wildtype mutations, and the treatment success rate for these patients (i.e., concomitant adjuvant temozolomide (TMZ) therapy) can be predicted via the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter. This evidence concerns the gene MGMT and glioblastoma.